MedTrace Logo

Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer

NCT03199144 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-06-23

No results posted yet for this study

Summary

The goal of the present study is to test if in situations of borderline resectable patients a neoadjuvant treatment combining Gemzar-Abraxane and stereotactic radiosurgery could increase the median OS rates above 30 months that means at least 12 months more than the 18-20 months generally described.

Conditions

  • Pancreatic Neoplasms

Interventions

DRUG

Chemotherapy

3 cycles of Gemzar-Abraxane

RADIATION

Stereotactic radiotherapy

Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days

PROCEDURE

Surgery

Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location

Sponsors & Collaborators

  • Centre Francois Baclesse, Luxembourg

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-20
Primary Completion
2021-03-19
Completion
2021-03-19

Countries

  • Luxembourg

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03199144 on ClinicalTrials.gov